Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

The two companies will scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.